Cytek Biosciences, Inc. (CTKB)
| Market Cap | 439.73M -6.9% |
| Revenue (ttm) | 204.17M +3.6% |
| Net Income | -74.00M |
| EPS | -0.58 |
| Shares Out | 129.14M |
| PE Ratio | n/a |
| Forward PE | 206.60 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,622,106 |
| Open | 3.320 |
| Previous Close | 3.355 |
| Day's Range | 3.320 - 3.595 |
| 52-Week Range | 2.370 - 6.180 |
| Beta | 1.23 |
| Analysts | Buy |
| Price Target | 5.69 (+67.11%) |
| Earnings Date | May 7, 2026 |
About CTKB
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek mu... [Read more]
Financial Performance
In 2025, Cytek Biosciences's revenue was $201.49 million, an increase of 0.52% compared to the previous year's $200.45 million. Losses were -$66.54 million, 1005.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for CTKB stock is "Buy." The 12-month stock price target is $5.69, which is an increase of 67.11% from the latest price.
News
Cytek Biosciences price target lowered to $4.75 from $5.50 at Stephens
Stephens lowered the firm’s price target on Cytek Biosciences (CTKB) to $4.75 from $5.50 and keeps an Overweight rating on the shares. While revenue was roughly in line and FY26…
Cytek Biosciences price target lowered to $5.50 from $6 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Cytek Biosciences (CTKB) to $5.50 from $6 and keeps an Equal Weight rating on the shares.
Cytek Biosciences Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 6% year-over-year to $44.1 million, led by strong U.S. instrument sales and double-digit growth in services and reagents. Recurring revenue rose to 35% of total, while net loss widened due to higher operating expenses. Full-year guidance of $205–$212 million was reaffirmed.
Cytek Biosciences Reports First Quarter 2026 Financial Results
FREMONT, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results f...
Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
FREMONT, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced that it will report financial results for the first quarter...
Cytek® Biosciences Celebrates One Year of Operations at Singapore Facility, Accelerating Growth and Regional Impact
Cytek Biosciences celebrates one year of operations at its Singapore facility, which has enhanced Cytek's manufacturing capacity and regional service.
Cytek Biosciences Transcript: TD Cowen 46th Annual Health Care Conference
Revenue grew 1% to $201.5M in 2025, outpacing a declining market and expanding global reach. Product innovation, especially Aurora Evo, and recurring revenue from services and reagents drive growth. APAC and clinical markets are key priorities for 2026.
Cytek Biosciences Earnings Call Transcript: Q4 2025
Record Q4 revenue and a return to growth in H2 2025 were driven by strong performance in APAC, EMEA, and recurring revenue streams. Despite higher operating expenses and non-cash tax write-offs, liquidity remains strong, and 2026 guidance anticipates continued growth and positive adjusted EBITDA.
Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook
FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results...
Cytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference
FREMONT, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming ...
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
FREMONT, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and ...
Cytek Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference
A leading cell analysis company reported $201 million in 2024 revenue, driven by market share gains, product innovation, and global expansion. Growth is expected to accelerate through 2026, supported by new product launches, increased reagent sales, and a balanced capital allocation strategy.
Cytek Biosciences reports preliminary Q4 revenue $62M, consensus $56.99M
Reports preliminary FY25 revenue $201M, consensus $196.71M. “Our fourth quarter revenue growth over the prior year represents a meaningful acceleration of growth compared to the prior quarters in 2025...
Cytek Biosciences Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Results
Company to present at the 44th Annual JP Morgan Healthcare Conference Company to present at the 44th Annual JP Morgan Healthcare Conference
Cytek Biosciences price target raised to $5 from $4 at TD Cowen
TD Cowen raised the firm’s price target on Cytek Biosciences (CTKB) to $5 from $4 and keeps a Buy rating on the shares. The firm adjusted price targets in the…
Cytek Biosciences Transcript: Piper Sandler 37th Annual Healthcare Conference
Double-digit growth continues in most segments, with Asia-Pacific and US markets strong and Europe stabilizing. Aurora Evo adoption is accelerating, reagent revenue is outpacing the market, and comprehensive solutions drive customer loyalty. EMEA challenges are seen as cyclical, with recovery expected.
Cytek Biosciences assumed with an Equal Weight at Morgan Stanley
Morgan Stanley assumed coverage of Cytek Biosciences (CTKB) with an Equal Weight rating and a price target of $6, up from $4. Life Science Tools and Diagnostics end market bright…
TIME Recognizes Cytek® Biosciences as One of America's Growth Leaders of 2026
FREMONT, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced its inclusion on TIME's 2026 list of America's Growth Leaders.
Cytek Biosciences price target lowered to $7.50 from $8 at Piper Sandler
Piper Sandler lowered the firm’s price target on Cytek Biosciences (CTKB) to $7.50 from $8 keeps an Overweight rating on the shares. The firm cites the company’s quarterly results for…
Cytek® Muse® Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year
FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that its Cytek ® Muse ® Micro cell analyzer has been named Drug Discovery Solution of the Year...
Cytek Biosciences to Participate in Upcoming Investor Conferences
FREMONT, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following...
Cytek Biosciences backs FY25 revenue view $196M-$205M, consensus $195.95M
The company said, “Cytek Biosciences (CTKB) reaffirms its 2025 revenue guidance of full year 2025 revenue to be in the range of $196 million to $205 million, representing growth of…
Cytek Biosciences reports Q3 EPS (4c), consensus 1c
Reports Q3 revenue $52.29M, consensus $51.14M. “Our third quarter results are encouraging and demonstrate the strength of our established brand and technology and our market leadership position,” said...
Cytek Biosciences Earnings Call Transcript: Q3 2025
Q3 2025 revenue grew 2% year-over-year to $52.3M, led by APAC and recurring revenue, while EMEA declined sharply. Adjusted EBITDA fell to $2.5M, and net loss was $5.5M. Full-year guidance of $196–$205M was reaffirmed, with strong APAC and recurring revenue momentum expected.
Cytek Biosciences Reports Third Quarter 2025 Financial Results
FREMONT, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results...